An Introduction to Rheumatic Diseases
Rheumatic autoimmune diseases are debilitating, painful conditions that cause substantial morbidity and mortality. They constitute a wide spectrum of disorders, which can be due to an abnormal immune response in a specific area, such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, or can be systemic, such as systemic lupus erythematosus and systemic sclerosis (scleroderma). They are challenging to diagnose since they often present with nonspecific symptoms. The management of these conditions has been transformed in recent years with the development of biological disease-modifying anti-rheumatic drugs and targeted synthetic disease modifying drugs. However, many patients fail to achieve remission or develop side effects.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Rheumatic Diseases Content
Nicholas Harvey, WCO21: The Royal Osteoporosis Society Research Roadmap
touchIMMUNOLOGY joins Professor Nicholas Harvey (University of Southampton, UK) at WCO21 to discuss the aims and hopes of the Royal Osteoporosis Society’s Research Roadmap initiative. Questions 1. What are the current unmet needs in osteoporosis and bone research? (00:27-01:26) 2. Please can you provide a short summary of the main aims of the Osteoporosis and […]
Emma Clark, WCO21: Novel Technologies for Skeletal Assessment
touchIMMUNOLOGY joins Professor Emma Clark (University of Bristol, UK) at WCO21 to discuss the current limitations of osteoporosis diagnosis and the latest novel technologies for skeletal assessment. Questions 1. Why is the diagnosis of osteoporosis so challenging? (00:16-02:13) 2. What are the strengths and limitations of currently available tools and services to diagnose osteoporosis? (02:13-04:28) […]
Philip Conaghan, WCO21: Tanezumab in the Treatment of Patients with Moderate-to-severe Osteoarthritis
touchIMMUNOLOGY joins Professor Philip Conaghan (University of Leeds, UK) at WCO21 to discuss improvements in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis. Questions 1. What is the rationale for the use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis? […]
Clive Kelly, EULAR 2021: Nintedanib in RA-ILD – Findings from the INBUILD Trial
It was a pleasure to meet with Dr Clive Kelly (University of Newcastle-upon-Tyne, Newcastle, UK) to talk around his presentation on ‘Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the INBUILD trial.‘ (OP0124), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021. […]
Rohit Aggarwal, ACR 2020 – Results of the ProDERM Study
We caught up with Rohit Aggarwal to discuss the efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis (Clinical Trial Identifier: NCT02728752). The abstract ‘Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)’ (ABSTRACT NUMBER: 0955) was presented […]
Maria Cinta Cid, ACR 2020 – Mavrilimumab in Patients with Giant Cell Arteritis (Part 2)
We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the results of the phase 2 trial evaluating the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission […]
Maria Cinta Cid, ACR 2020 – Mavrilimumab in Patients with Giant Cell Arteritis (Part 1)
We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with […]
Ihsane Hmamouchi, ACR 2020 – Clomipramine for Chronic Lumbar Radicular Pain
We were delighted to speak to Ihsane Hmamouchi regarding the use of clomipramine for the treatment of chronic lumbar radicular pain. The abstract ‘Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial’ (ABSTRACT NUMBER: 0962) was presented at the virtual ACR Convergence 2020, 5-9 November 2020. Questions What is the rationale for […]
Daniel Joe Lovell, ACR 2020 – Results from the Ongoing Phase IV PRCSG/PRINTO Registry
We caught up with Daniel Joe Lovell (University of Cincinnati School of Medicine, Cincinnati, OH, USA) to discuss the effectiveness of abatacept in juvenile idiopathic arthritis categories. The abstract ‘Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry’ (ABSTRACT NUMBER: 0714) was presented at the virtual ACR Convergence 2020, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!